Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 8 of 8 results for mesalazine

  1. Crohn's disease: management (NG129)

    This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.

  2. 5-aminosalicylate (5-ASA) treatment:- Following successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no treatment?

    successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no...

  3. Accessibility changes: notes for developers (ECD6)

    This is a summary of the most common accessibility changes we are making in guidelines, and why

  4. Ozanimod for treating moderately to severely active ulcerative colitis (TA828)

    Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.

  5. What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in the post-surgical period of Crohn's disease?

    The committee also reviewed theevidence for aminosalicylates (such as mesalazine). The evidence on relapse rates...

  6. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

  7. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  8. Research recommendations

    successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no...